Peptide and GLP-1 statistics (2026)

Key peptide statistics

• 35 of 82 peptides we track have an FDA approval on record (43%). The other 47 do not. Regulatory tracker
• 19 of 47 peptides without an FDA approval have no randomized controlled trial in people (40%). How we grade evidence
• 16 of 82 have only animal or laboratory studies, with no indexed study in people. All peptides
• 17 are on FDA's list of compounding nominations withdrawn by their nominators, which leaves them outside FDA's interim compounding policy. Only 3 are in FDA's Category 1, where compounding may continue while FDA reviews them. Legal guide
• 29 of 50 states allow a telehealth prescription without a live visit; 7 do not, and in 14 the state law we checked does not settle it. In 15 of the 29, the law also says an online questionnaire alone is not enough. State law pages
• 43 of 82 are prohibited in sport under the WADA Prohibited List: named on it, in a named class, or covered by its rule for substances with no government approval. Some apply only in competition or only to male athletes.
• 19 FDA warning letters in our file name 34 of the compounds we cover (for follistatin, the letter does not say which form), sent to compounding pharmacies, outsourcing facilities, ingredient distributors, and online sellers.
• 62 dated regulatory actions are on our tracker, 12 of them in 2026, each linked to its primary source. Regulatory tracker

How many peptides are FDA approved?

35 of the 82 peptides we track have an FDA approval on record. An approval on record does not mean a product is on the market today: some approved products have since been discontinued, and each peptide page says so where that applies. The table counts every peptide by its current status. The methodology defines each status.

How strong is the evidence for peptides?

Each peptide gets one grade from the strongest study design indexed in PubMed. A grade describes how the evidence was gathered, not whether the peptide works: a randomized trial can find no benefit. The 315 PubMed IDs cited on peptide pages each link to the PubMed record.

How many peptides are banned in sport?

Status under the World Anti-Doping Agency Prohibited List in force. "Unclear" means the substance is not named and the list's class rules do not settle it; a tested athlete should ask their anti-doping organization.

How many Americans take GLP-1 drugs?

These figures are not ours. Each is quoted from the organization that measured it, with who was surveyed and when.

• 12% of US adults say they are currently taking a GLP-1 drug, to lose weight or to treat a chronic condition. KFF Health Tracking Poll, fielded October 27 to November 2, 2025, online and by telephone among a nationally representative sample of 1,350 US adults. KFF Health Tracking Poll
• 18% of US adults say they have taken a GLP-1 drug at some point. Same KFF poll, fielded October 27 to November 2, 2025 (1,350 US adults). The May 2024 poll put this at 12%. KFF Health Tracking Poll
• 26.5% of US adults with diagnosed diabetes used a GLP-1 injectable in 2024. CDC National Center for Health Statistics, Data Brief No. 537 (August 2025), from the 2024 National Health Interview Survey. CDC NCHS Data Brief No. 537

How many adverse event reports name GLP-1 drugs?

Summing the FDA Adverse Event Reporting System (FAERS) report counts for each FDA approved GLP-1 and incretin peptide gives 12,083 in 2016 and 98,396 in 2025. A report that names two of these drugs is counted twice. Report counts are not rates: they rise with how many people take a drug, and a report does not show the drug caused the event. Counts pulled from openFDA on Sep 22, 2026. State of Peptides, 2026 Q3

Where do these numbers come from?

• Our counts come from the records behind this site. Each record cites its primary sources: FDA, the Federal Register, WADA, state boards, and PubMed. The full dataset is free to download on the data page under CC BY 4.0.
• "Tracked" means the 82 peptides with a record here. It is not every peptide that exists or is sold, so these are shares of our list, not of the market.
• Outside figures are quoted as published and dated. We do not adjust or combine them.
• More detail, charts, and downloads are in the State of Peptides, 2026 Q3 report and the press kit. Found an error? Email hello@peptideagent.ai and we will correct it with a date.